1
Announcements
Trials
Conditions
Other
1
Drug Classes
Anti-PD-1
97
Anti-PD-L1
30
Anti-CD20
24
Platinum agent
21
Immunomodulatory drugs (IMiDs)
20
Taxane
20
VEGFR inhibitor
20
BTK inhibitor
18
Bcr-Abl inhibitor
18
Anti-CD38
17
PARP inhibitor
17
Anti-HER2
16
Anti-VEGFR
16
BRAF inhibitor
16
EGFR inhibitor
16
Proteasome inhibitor
16
ALK inhibitor
14
Anti-CD19 CAR T-cell
14
MEK inhibitor
13
Anti-CTLA-4
12
Anti-EGFR
12
Anti-HER2 ADC
11
MTOR inhibitor
11
Second-generation nonsteroidal antiandrogen
10
Antifolate
9
CDK inhibitor
9
Multikinase inhibitor
9
Nitrogen mustard
9
Pyrimidine analog
9
RET inhibitor
9
ERBB2 inhibitor
8
IDH inhibitor
8
Anti-CD30 ADC
7
Estrogen receptor inhibitor
7
Fluoropyrimidine
7
Megakaryocyte growth factor
7
Alkylating agent
6
Anthracycline
6
Bcl-2 inhibitor
6
Anti-CD20-CD3 bispecific
5
Anti-EGFR-HGFR bispecific
5
Anti-nectin-4 ADC
5
Asparagine-specific enzyme
5
DNA methyltransferase inhibitor
5
FGFR inhibitor
5
JAK inhibitor
5
Radioactive agent
5
Anti-BCMA-CD3 bispecific
4
Anti-CD19-CD3 bispecific
4
HDAC inhibitor
4
KRAS inhibitor
4
MET inhibitor
4
Multi-ingredient
4
PI3K delta inhibitor
4
Anti-RANKL
3
Anti-TACSTD2 ADC
3
Anti-TROP2 ADC
3
CYP17 inhibitor
3
FLT3 inhibitor
3
HIF-2a inhibitor
3
KMT2A inhibitor
3
Non-taxane microtubule dynamics inhibitor
3
PDGFR inhibitor
3
PI3K alpha inhibitor
3
ROS1 inhibitor
3
TRK inhibitor
3
Topoisomerase I inhibitor
3
XPO1 inhibitor
3
AKT1 inhibitor
2
Anti-BCMA CAR T-cell
2
Anti-BCMA ADC
2
Anti-CD19
2
Anti-CD22 ADC
2
Anti-CD33 ADC
2
Anti-CD79B ADC
2
Anti-DLL3-CD3 bispecific
2
Anti-FOLR1 ADC
2
Anti-GD2
2
Anti-HER2-HER3 bispecific
2
Anti-TF ADC
2
Aromatase inhibitor third generation
2
EZH inhibitor
2
Erythrocyte growth factor
2
Factor IXa/Xa bridging
2
GnRH antagonist
2
Granulocyte colony-stimulating factor
2
IL-3 fused immunotoxin
2
Low molecular weight heparin
2
Purine analog
2
SMO inhibitor
2
STAMP inhibitor
2
TGF-beta inhibitor
2
Topoisomerase II inhibitor
2
Adenovirus vector
1
Anti-C5
1
Anti-CCR4
1
Anti-CD19 ADC
1
Anti-CD22 immunotoxin
1
Anti-CLDN18.2
1
Anti-CSF1R
1
Anti-GPRC5D-CD3 bispecific
1
Anti-HER2 bispecific
1
Anti-IFNg
1
Anti-IL-2R immunotoxin
1
Anti-IL-6
1
Anti-MAGE-A4 SPEAR T-cell
1
Anti-P-selectin
1
Anti-PDGFR
1
Anti-SLAMF7
1
Anti-c-Met ADC
1
Anti-dabigatran antibody fragment
1
Anti-vWF
1
Antimetabolite
1
Bispecific gp100 peptide-HLA-directed CD3 T-cell engager
1
CSF1R inhibitor
1
CXCR4 inhibitor
1
Cellular therapy
1
Chemotherapy protective agent
1
EDTA derivative
1
Factor Xa inhibitor
1
Gamma secretase inhibitor
1
Glucocorticoid receptor antagonist
1
Hedgehog pathway inhibitor
1
Hemoglobin S polymerization inhibitor
1
IL-15 receptor alpha fusion protein
1
Interferon
1
Iron chelating agent
1
Mononuclear cell vaccine
1
Oncolytic viral therapy
1
Ornithine decarboxylase inhibitor
1
Profibrinolytic
1
Proteolysis-targeting chimera estrogen receptor degrader
1
ROCK2 inhibitor
1
Replacement therapy
1
SYK inhibitor
1
Selective estrogen receptor modulator
1
Somatostatin analog
1
Telomerase inhibitor
1
Triazene
1
Vinca alkaloid
1
Somatostatin analog
×
Clear all
1 Announcement
2014-12-16
Lanreotide
Drug
Somatuline Depot
(lanreotide)
· Somatostatin analog